The structure of TMEM16A in a blocker-bound, partially open state presented here may thus lead to the rational design of specific small molecules for its therapeutic targeting in conditions such as hypertension, asthma, and cystic fibrosis. The gene discussed is ANO1; the disease is hypertensive disorder.